StockMacro
Company, fund or insider

Help

Menu

Prothena

$8.22 -18% in 6 monthsMarket cap $422.1M

PRTA on XNAS, Health Care, Prothena Corporation plc, job postings

Measures activity, not value. Not investment advice.

Revenue jumped 347% to $52.7M while short interest stands at 15% of shares.

  • GoodInsiders bought $9.8M of shares in 90 days and sold none
  • GoodCash of $271.4M against a net loss of $24M over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Industry
Pharmaceutical preparations (Health Care)
Employees
67
Website
prothena.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $620K, net loss $16.5M.
Quarter to 31 Dec 2021: revenue –, net income -$33.2MQuarter to 31 Mar 2022: revenue $1.2M, net income -$36.3MQuarter to 31 Mar 2022: revenue $1.2M, net income -$36.3MQuarter to 30 Jun 2022: revenue $1.3M, net income -$41.2MQuarter to 30 Jun 2022: revenue $1.3M, net income -$41.2MQuarter to 30 Sep 2022: revenue $1.5M, net income -$45.8MQuarter to 30 Sep 2022: revenue $1.5M, net income -$45.8MQuarter to 31 Dec 2022: revenue $49.9M, net income $6.3MQuarter to 31 Dec 2022: revenue $49.9M, net income $6.3MQuarter to 31 Mar 2023: revenue $2.2M, net income -$46.9MQuarter to 31 Mar 2023: revenue $2.2M, net income -$46.9MQuarter to 30 Jun 2023: revenue $4.0M, net income -$54.6MQuarter to 30 Jun 2023: revenue $4.0M, net income -$54.6MQuarter to 30 Sep 2023: revenue $84.9M, net income $21.9MQuarter to 30 Sep 2023: revenue $84.9M, net income $21.9MQuarter to 31 Dec 2023: revenue $316K, net income -$67.5MQuarter to 31 Dec 2023: revenue $316K, net income -$67.5MQuarter to 31 Mar 2024: revenue $50K, net income -$72.2MQuarter to 31 Mar 2024: revenue $50K, net income -$72.2MQuarter to 30 Jun 2024: revenue $132.0M, net income $66.9MQuarter to 30 Jun 2024: revenue $132.0M, net income $66.9MQuarter to 30 Sep 2024: revenue $970K, net income -$59.0MQuarter to 30 Sep 2024: revenue $970K, net income -$59.0MQuarter to 31 Dec 2024: revenue $2.1M, net income -$58.0MQuarter to 31 Dec 2024: revenue $2.1M, net income -$58.0MQuarter to 31 Mar 2025: revenue $2.8M, net income -$60.2MQuarter to 31 Mar 2025: revenue $2.8M, net income -$60.2MQuarter to 30 Jun 2025: revenue $4.4M, net income -$125.8MQuarter to 30 Jun 2025: revenue $4.4M, net income -$125.8MQuarter to 30 Sep 2025: revenue $2.4M, net income -$36.5MQuarter to 30 Sep 2025: revenue $2.4M, net income -$36.5MQuarter to 31 Dec 2025: revenue –, net income -$21.6MQuarter to 31 Mar 2026: revenue $51.1M, net income $32.7MQuarter to 31 Mar 2026: revenue $51.1M, net income $32.7MQuarter to 30 Jun 2026: revenue $1.0M, net income -$18.6MQuarter to 30 Jun 2026: revenue $1.0M, net income -$18.6MQuarter to 30 Sep 2026: revenue $620K, net income -$16.5MQuarter to 30 Sep 2026: revenue $620K, net income -$16.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $132.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$620K-$16.5M
30 Jun 2026$1.0M-$18.6M
31 Mar 2026$51.1M$32.7M
31 Dec 2025–-$21.6M
30 Sep 2025$2.4M-$36.5M
30 Jun 2025$4.4M-$125.8M
31 Mar 2025$2.8M-$60.2M
31 Dec 2024$2.1M-$58.0M
30 Sep 2024$970K-$59.0M
30 Jun 2024$132.0M$66.9M
31 Mar 2024$50K-$72.2M
31 Dec 2023$316K-$67.5M
30 Sep 2023$84.9M$21.9M
30 Jun 2023$4.0M-$54.6M
31 Mar 2023$2.2M-$46.9M
31 Dec 2022$49.9M$6.3M
30 Sep 2022$1.5M-$45.8M
30 Jun 2022$1.3M-$41.2M
31 Mar 2022$1.2M-$36.3M
31 Dec 2021–-$33.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $52.7M $11.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +347% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$24.0M -$280.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.48 -$5.21
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -64.6% – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -45.4% – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -8.5% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $271.4M $330.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$271.4M (net cash) -$330.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.24
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 8.0 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.9 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.6 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ProthenaPRTA (this company) $422.1Mloss8.0+347%-45.4%
ArvinasARVN $423.0Mloss1.5-12%-3.5%
CorMedixCRMD $419.2M6.61.0–15.5%
Ovid TherapeuticsOVID $415.2Mloss286-78%–
EvolusEOLS $431.5Mloss1.3+14%-9.6%
Indaptus TherapeuticsINDP $433.2Mloss–––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$9.8M

bought $9.8M, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-1.6%

180 13F filers vs 183

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

90%

46.3M shares held by 13F filers (30 Sep 2026) of 51.3M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

15%

7.9M shares sold short (30 Oct 2026) of 51.3M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

15.7

7.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.4%

7.9M shares sold short in the report before, 7.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

45%

45% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 58%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

7

7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $8.22 on 20 Nov 2026, -18% over 12 months (12-month range $7.89 to $11.51)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $13.5M in the last 12 months (the 12 months before: -$48.1M).
Revenue per quarter. Revenue $620K in the latest quarter, -74% on a year earlier.
Institutional holders (13F filers). 180 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
29 Oct 20268-K and other filingsA major agreement ended
2 Oct 20268-K and other filingsDirector or officer change
2 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2026Sharp changeQuarterly revenue change: quarterly revenue change, 51.1M vs usual 2.3M (2026-03-31); 18.1x the same period a year earlier
12 Dec 20258-K and other filingsDirector or officer change
12 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 46 vs usual 23 (2025-06-30); 2.0x the same period a year earlier
30 Jul 20258-K and other filingsDirector or officer change
18 Jun 20258-K and other filingsDirector or officer change
18 Jun 20258-K and other filingsRestructuring costs announced
16 May 20258-K and other filingsDirector or officer change
16 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Dec 20248-K and other filingsDirector or officer change
30 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Sep 20248-K and other filingsDirector or officer change
27 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 132.0M vs usual 1.8M (2024-06-30); 32.8x the same period a year earlier
17 May 20248-K and other filingsDirector or officer change
21 Feb 20248-K and other filingsDirector or officer change
21 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Dec 2023Sharp changeShort interest spike: short interest spike, 6.8M vs usual 3.5M (2023-11-30); 3.0x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 6.2M vs usual 3.4M (2023-11-15); 2.8x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 6.5M vs usual 3.3M (2023-10-31); 2.7x the same period a year earlier
7 Nov 2023Sharp changeQuarterly revenue change: quarterly revenue change, 84.9M vs usual 3.1M (2023-09-30); 55.9x the same period a year earlier
19 May 20238-K and other filingsDirector or officer change
16 May 20238-K and other filingsDirector or officer change
28 Apr 20238-K and other filingsDirector or officer change
28 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Sep 20228-K and other filingsDirector or officer change
1 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 May 20228-K and other filingsDirector or officer change
20 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Mar 2022Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.7M (2022-02-15); 4.6x the same period a year earlier
Insider net buying (open market)
Month from 1 Nov 2021: -$262K published
Month from 1 Jan 2022: $11.0M published
Month from 1 Apr 2022: -$372K published
Month from 1 May 2022: $0 published
Month from 1 Jul 2022: -$3.0M published
Month from 1 Aug 2022: -$3.0M published
Month from 1 Sep 2022: -$515K published
Month from 1 Oct 2022: -$12.7M published
Month from 1 Nov 2022: -$3.0M published
Month from 1 Dec 2022: -$2.7M published
Month from 1 Jan 2023: -$2.0M published
Month from 1 Feb 2023: -$533K published
Month from 1 Mar 2023: -$3.0M published
Month from 1 Apr 2023: -$777K published
Month from 1 May 2023: -$11.6M published
Month from 1 Jun 2023: -$5.1M published
Month from 1 Jul 2023: -$2.0M published
Month from 1 Aug 2023: -$1.5M published
Month from 1 Sep 2023: -$1.1M published
Month from 1 Oct 2023: -$625K published
Month from 1 Dec 2023: -$356K published
Month from 1 Jan 2024: -$170K published
Month from 1 May 2025: -$48.1M published
Month from 1 May 2026: $981K published
Month from 1 Jun 2026: $2.1M published
Month from 1 Jul 2026: -$136K published
Month from 1 Aug 2026: $763K published
Month from 1 Sep 2026: $2.0M published
Month from 1 Oct 2026: $6.2M published
Month from 1 Nov 2026: $1.6M published
Revenue per quarter
Quarter ended 31 Mar 2022: $1.2M, +621% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.3M, -98% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $1.5M, -99% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $49.9M; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $2.2M, +88% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $4.0M, +206% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $84.9M, +5494% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $316K, -99% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $50K, -98% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $132.0M, +3185% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $970K, -99% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $2.1M, +572% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $2.8M, +5556% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $4.4M, -97% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $2.4M, +149% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $51.1M, +1706% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $1.0M, -77% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $620K, -74% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 179; public on 14 Feb 2022
31 Mar 2022 report: 161; public on 16 May 2022
30 Jun 2022 report: 152; public on 15 Aug 2022
30 Sep 2022 report: 167; public on 14 Nov 2022
31 Dec 2022 report: 186; public on 14 Feb 2023
31 Mar 2023 report: 179; public on 15 May 2023
30 Jun 2023 report: 185; public on 14 Aug 2023
30 Sep 2023 report: 177; public on 14 Nov 2023
31 Dec 2023 report: 171; public on 14 Feb 2024
31 Mar 2024 report: 159; public on 15 May 2024
30 Jun 2024 report: 150; public on 14 Aug 2024
30 Sep 2024 report: 155; public on 14 Nov 2024
31 Dec 2024 report: 166; public on 14 Feb 2025
31 Mar 2025 report: 157; public on 15 May 2025
30 Jun 2025 report: 180; public on 14 Aug 2025
30 Sep 2025 report: 180; public on 14 Nov 2025
31 Dec 2025 report: 176; public on 17 Feb 2026
31 Mar 2026 report: 178; public on 15 May 2026
30 Jun 2026 report: 183; public on 14 Aug 2026
30 Sep 2026 report: 180; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $8.4M (30 Sep 2026), 83% below its normal quarter of $50.4M; higher than 12% of its own history.
  • Insider net buying (open market): Insiders bought a net $13.5M in the last 12 months (the 12 months before: -$48.1M).
  • Revenue per quarter: Revenue $620K in the latest quarter, -74% on a year earlier.
  • Institutional holders (13F filers): 180 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: no sales; 10 purchases, $9.8M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026William P Scully10% ownerBuy50,000$8.09$405KForm 4
10 Nov 2026William P Scully10% ownerBuy140,000$8.53$1.2MForm 4
26 Oct 2026William P Scully10% ownerBuy150,000$8.15$1.2MForm 4
15 Oct 2026William P Scully10% ownerBuy110,000$8.36$920KForm 4
9 Oct 2026William P Scully10% ownerBuy215,000$8.47$1.8MForm 4
6 Oct 2026William P Scully10% ownerBuy100,000$8.57$857KForm 4
30 Sep 2026William P Scully10% ownerBuy162,000$8.68$1.4MForm 4
29 Sep 2026William P Scully10% ownerBuy103,500$8.60$890KForm 4

180 institutions reported shares at the end of Q3 2026, 90% of the shares outstanding; 18 opened a position, 21 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)7.0M13.7%$58.8M-185K-2.6%
BlackRock, Inc.5.7M11.2%$48.1M+868K+18%
Rubric Capital Management LP5.0M9.74%$41.9MNo change
Acadian Asset Management LLC2.1M4.03%+58K+2.9%
State Street Corp1.8M3.59%$15.4M-552K-23%
Vanguard Portfolio Management LLC1.6M3.06%$13.2M-82K-5.0%
ADAR1 Capital Management, LLC1.5M2.96%$12.8M-32K-2.1%
D. E. Shaw & Co., Inc.1.4M2.80%$12.1M-171K-11%
Two Sigma Investments, LP1.2M2.35%$10.1M-61K-4.8%
Federated Hermes, Inc.1.1M2.22%$9.5M+54K+5.0%

Company events

All 47 company events

In 12 months: 2 director or officer changes, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Oct 2026A major agreement ended8-K
2 Oct 2026Director or officer change8-K
12 Dec 2025Director or officer change8-K
30 Jul 2025Director or officer change8-K
18 Jun 2025Director or officer change; Restructuring costs announced8-K
16 May 2025Director or officer changeSame filing: shareholder vote results8-K
30 Dec 2024Director or officer change8-K
27 Sep 2024Director or officer change8-K

Reported lobbying spend: $20K in Q4 2018, $20K in Q3 2018. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Mar 2019EndedHorizon Government Affairsfor Prothena Biosciences IncNot statedFiling
10 Feb 2015NewHorizon Government Affairsfor Prothena Biosciences Inc21st Century Cures, Therapy development and innovationHealth issuesFiling

The 5 newest of 38 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 Nov 2023confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Prothena (PRTA): reported revenue of $84.9M for the quarter ended 30 Sep 2023, 56× the same quarter last year, while it had 6.5M shares sold short in the 31 Oct 2023 report, 2.7× the same report last year. Two unrelated kinds of activity within 35 days.

  • Financials: Quarterly revenue change, became public on 7 Nov 2023
  • Short interest and volume: Short interest spike, became public on 10 Nov 2023
  • Short interest and volume: Short interest spike, became public on 28 Nov 2023
  • Short interest and volume: Short interest spike, became public on 12 Dec 2023
2021-06-30: $60.1M2021-09-30: $139.2M2022-03-31: $1.2M2022-06-30: $1.3M2022-09-30: $1.5M2022-12-31: $49.9M2023-03-31: $2.2M2023-06-30: $4.0M2023-09-30: $84.9M
The quarter ended 30 Sep 2023 against the 8 quarters before it. this quarterearliernormal: $3.1M
See the evidence (4 changes)

Financials: Quarterly revenue change became public on 7 Nov 2023

Prothena reported revenue of $84.9M for the quarter ended 30 Sep 2023, 56× the same quarter last year.

This period
$84.9M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$3.1M
Typical spread (median absolute deviation)
$1.9M
How far from its usual level
+29.6
Same quarter last year
$1.5M
History used
3,835 days
2021-06-30: $60.1M2021-09-30: $139.2M2022-03-31: $1.2M2022-06-30: $1.3M2022-09-30: $1.5M2022-12-31: $49.9M2023-03-31: $2.2M2023-06-30: $4.0M2023-09-30: $84.9M
the quarter ended 30 Sep 20238 earlier quartersnormal: $3.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 Nov 2023

Prothena had 6.5M shares sold short in the 31 Oct 2023 report, 2.7× the same report last year.

This period
6.5M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
411K
How far from its usual level
+5.3
Same report last year
2.4M
History used
2,132 days
2022-10-31: 2.4M2022-11-15: 2.2M2022-11-30: 2.3M2022-12-15: 2.4M2022-12-30: 2.6M2023-01-13: 2.9M2023-01-31: 2.8M2023-02-15: 3.0M2023-02-28: 3.1M2023-03-15: 3.4M2023-03-31: 3.7M2023-04-14: 3.3M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 3.3M2023-06-15: 3.7M2023-06-30: 3.5M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.7M2023-08-31: 4.1M2023-09-15: 4.3M2023-09-29: 4.4M2023-10-13: 5.1M2023-10-31: 6.5M
the 31 Oct 2023 report24 earlier reportsnormal: 3.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Nov 2023

Prothena had 6.2M shares sold short in the 15 Nov 2023 report, 2.8× the same report last year.

This period
6.2M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
375K
How far from its usual level
+5.1
Same report last year
2.2M
History used
2,147 days
2022-11-15: 2.2M2022-11-30: 2.3M2022-12-15: 2.4M2022-12-30: 2.6M2023-01-13: 2.9M2023-01-31: 2.8M2023-02-15: 3.0M2023-02-28: 3.1M2023-03-15: 3.4M2023-03-31: 3.7M2023-04-14: 3.3M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 3.3M2023-06-15: 3.7M2023-06-30: 3.5M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.7M2023-08-31: 4.1M2023-09-15: 4.3M2023-09-29: 4.4M2023-10-13: 5.1M2023-10-31: 6.5M2023-11-15: 6.2M
the 15 Nov 2023 report24 earlier reportsnormal: 3.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Dec 2023

Prothena had 6.8M shares sold short in the 30 Nov 2023 report, 3.0× the same report last year.

This period
6.8M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
459K
How far from its usual level
+4.9
Same report last year
2.3M
History used
2,162 days
2022-11-30: 2.3M2022-12-15: 2.4M2022-12-30: 2.6M2023-01-13: 2.9M2023-01-31: 2.8M2023-02-15: 3.0M2023-02-28: 3.1M2023-03-15: 3.4M2023-03-31: 3.7M2023-04-14: 3.3M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 3.3M2023-06-15: 3.7M2023-06-30: 3.5M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.7M2023-08-31: 4.1M2023-09-15: 4.3M2023-09-29: 4.4M2023-10-13: 5.1M2023-10-31: 6.5M2023-11-15: 6.2M2023-11-30: 6.8M
the 30 Nov 2023 report24 earlier reportsnormal: 3.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Nov 2021confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Prothena (PRTA): reported revenue of $139.2M for the quarter ended 30 Sep 2021, 886× the same quarter last year, while it saw 46 13F filers open a new position in the quarter ended 30 Sep 2021, 2.7× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly revenue change, became public on 9 Nov 2021
  • Institutional holdings: Many funds opening a new position, became public on 15 Nov 2021
2019-09-30: $205K2019-12-31: $256K2020-03-31: $141K2020-06-30: $195K2020-09-30: $157K2020-12-31: $360K2021-03-31: $160K2021-06-30: $60.1M2021-09-30: $139.2M
The quarter ended 30 Sep 2021 against the 8 quarters before it. this quarterearliernormal: $200K
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 9 Nov 2021

Prothena reported revenue of $139.2M for the quarter ended 30 Sep 2021, 886× the same quarter last year.

This period
$139.2M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$200K
Typical spread (median absolute deviation)
$50K
How far from its usual level
+139.0
Same quarter last year
$157K
History used
3,105 days
2019-09-30: $205K2019-12-31: $256K2020-03-31: $141K2020-06-30: $195K2020-09-30: $157K2020-12-31: $360K2021-03-31: $160K2021-06-30: $60.1M2021-09-30: $139.2M
the quarter ended 30 Sep 20218 earlier quartersnormal: $200K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 Nov 2021

Prothena saw 46 13F filers open a new position in the quarter ended 30 Sep 2021, 2.7× the same quarter last year.

This period
46 (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
18
Typical spread (median absolute deviation)
3
How far from its usual level
+6.3
Same quarter last year
17
History used
2,922 days
2019-09-30: 122019-12-31: 162020-03-31: 102020-06-30: 202020-09-30: 172020-12-31: 222021-03-31: 192021-06-30: 292021-09-30: 46
the quarter ended 30 Sep 20218 earlier quartersnormal: 18

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 50,000 shares of PRTA ($404,680)

  2. 10 Nov 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 140,000 shares of PRTA ($1.2M)

  3. 29 Oct 2026Filings record

    A major agreement ended

  4. 26 Oct 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 150,000 shares of PRTA ($1.2M)

  5. 15 Oct 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 110,000 shares of PRTA ($920,049)

  6. 9 Oct 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 215,000 shares of PRTA ($1.8M)

  7. 6 Oct 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 100,000 shares of PRTA ($857,240)

  8. 2 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 2 Oct 2026Filings record

    Director or officer change

  10. 1 Oct 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 162,000 shares of PRTA ($1.4M) (dated 30 Sep 2026)

  11. 30 Sep 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 103,500 shares of PRTA ($890,100) (dated 29 Sep 2026)

  12. 22 Sep 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 100,000 shares of PRTA ($843,000) (dated 21 Sep 2026)

  13. 4 Sep 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 27,000 shares of PRTA ($255,690) (dated 3 Sep 2026)

  14. 22 Aug 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 50,000 shares of PRTA ($439,500) (dated 21 Aug 2026)

  15. 11 Aug 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 37,500 shares of PRTA ($323,250) (dated 10 Aug 2026)

  16. 19 Jun 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 20,000 shares of PRTA ($158,000) (dated 18 Jun 2026)

  17. 13 Jun 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 125,000 shares of PRTA ($1.0M) (dated 12 Jun 2026)

  18. 6 Jun 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 50,000 shares of PRTA ($465,500) (dated 5 Jun 2026)

  19. 4 Jun 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 50,000 shares of PRTA ($471,500) (dated 3 Jun 2026)

  20. 27 May 2026Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 100,000 shares of PRTA ($981,000) (dated 26 May 2026)

  21. 12 May 2026Financials change

    reported revenue of $51.1M for the quarter ended 31 Mar 2026, 18× the same quarter last year.

    Same quarter last year: $2.8M; its normal quarter is $2.3M.

    See the evidence
    This period
    $51.1M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $2.3M
    Typical spread (median absolute deviation)
    $1.6M
    How far from its usual level
    +20.2
    Same quarter last year
    $2.8M
    History used
    4,748 days
    2023-12-31: $316K2024-03-31: $50K2024-06-30: $132.0M2024-09-30: $970K2024-12-31: $2.1M2025-03-31: $2.8M2025-06-30: $4.4M2025-09-30: $2.4M2026-03-31: $51.1M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $2.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 12 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 12 Dec 2025Filings record

    Director or officer change

  24. 14 Aug 2025Institutional holdings change

    saw 46 13F filers open a new position in the quarter ended 30 Jun 2025, 2.0× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 23.

    See the evidence
    This period
    46 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    23
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.4
    Same quarter last year
    23
    History used
    4,291 days
    2023-06-30: 292023-09-30: 232023-12-31: 272024-03-31: 202024-06-30: 232024-09-30: 162024-12-31: 232025-03-31: 152025-06-30: 46
    the quarter ended 30 Jun 20258 earlier quartersnormal: 23

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  25. 30 Jul 2025Filings record

    Director or officer change

  26. 18 Jun 2025Filings record

    Director or officer change

  27. 18 Jun 2025Filings record

    Restructuring costs announced

  28. 16 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 16 May 2025Filings record

    Director or officer change

  30. 3 May 2025Insiders record

    SCULLY WILLIAM P (ten percent owner) bought 207,436 shares of PRTA ($2.8M) (dated 2 May 2025)

  31. 30 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 30 Dec 2024Filings record

    Director or officer change

  33. 27 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 27 Sep 2024Filings record

    Director or officer change

  35. 13 Aug 2024Financials change

    reported revenue of $132.0M for the quarter ended 30 Jun 2024, 33× the same quarter last year.

    Same quarter last year: $4.0M; its normal quarter is $1.8M.

    See the evidence
    This period
    $132.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $1.8M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +52.9
    Same quarter last year
    $4.0M
    History used
    4,109 days
    2022-06-30: $1.3M2022-09-30: $1.5M2022-12-31: $49.9M2023-03-31: $2.2M2023-06-30: $4.0M2023-09-30: $84.9M2023-12-31: $316K2024-03-31: $50K2024-06-30: $132.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $1.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  36. 17 May 2024Filings record

    Director or officer change

  37. 21 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 21 Feb 2024Filings record

    Director or officer change

  39. 12 Dec 2023Short interest and volume change

    had 6.8M shares sold short in the 30 Nov 2023 report, 3.0× the same report last year.

    Same report last year: 2.3M; its normal report is 3.5M.

    See the evidence
    This period
    6.8M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    459K
    How far from its usual level
    +4.9
    Same report last year
    2.3M
    History used
    2,162 days
    2022-11-30: 2.3M2022-12-15: 2.4M2022-12-30: 2.6M2023-01-13: 2.9M2023-01-31: 2.8M2023-02-15: 3.0M2023-02-28: 3.1M2023-03-15: 3.4M2023-03-31: 3.7M2023-04-14: 3.3M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 3.3M2023-06-15: 3.7M2023-06-30: 3.5M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.7M2023-08-31: 4.1M2023-09-15: 4.3M2023-09-29: 4.4M2023-10-13: 5.1M2023-10-31: 6.5M2023-11-15: 6.2M2023-11-30: 6.8M
    the 30 Nov 2023 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 28 Nov 2023Short interest and volume change

    had 6.2M shares sold short in the 15 Nov 2023 report, 2.8× the same report last year.

    Same report last year: 2.2M; its normal report is 3.4M.

    See the evidence
    This period
    6.2M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    375K
    How far from its usual level
    +5.1
    Same report last year
    2.2M
    History used
    2,147 days
    2022-11-15: 2.2M2022-11-30: 2.3M2022-12-15: 2.4M2022-12-30: 2.6M2023-01-13: 2.9M2023-01-31: 2.8M2023-02-15: 3.0M2023-02-28: 3.1M2023-03-15: 3.4M2023-03-31: 3.7M2023-04-14: 3.3M2023-04-28: 3.3M2023-05-15: 3.2M2023-05-31: 3.3M2023-06-15: 3.7M2023-06-30: 3.5M2023-07-14: 3.6M2023-07-31: 3.7M2023-08-15: 3.7M2023-08-31: 4.1M2023-09-15: 4.3M2023-09-29: 4.4M2023-10-13: 5.1M2023-10-31: 6.5M2023-11-15: 6.2M
    the 15 Nov 2023 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 91 entries; narrow the window or the kind of data to see older ones.

Not listed: 266 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001559053
Ticker
PRTA
Domain
prothena.com
Employer name
prothena biosciences (1 unverified)
Hq location
L2|DUBLIN 2|D02 V (1 unverified)
Lobbying client
prothena biosciences
Name
Neotope Corp Ltd, Othair Prothena Limited, Prothena Biosciences Limited, Prothena Corporation plc and 4 more
  • Federal lobbying disclosures (LDA)2 records, 49 data points10 Feb 2015 to 31 Mar 2019
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)162 records7 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)793 data points31 Dec 2010 to 29 Oct 2026
  • SEC Form 4 insider transactions167 records, 524 data points6 Jan 2016 to 19 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026